Literature DB >> 11801272

Primary drug treatment for glaucoma: beta-blockers versus other medications.

Robert L Stamper1, Stephen A Wigginton, Eve J Higginbotham.   

Abstract

This set of Viewpoints articles examines the merits of beta-blockers versus other medications as the primary drug treatment for glaucoma. Ophthalmologists must balance issues such as efficacy, compliance, cost, and side effects when deciding on the appropriate medication to prescribe. Dr. Stamper stresses the advantages of tailoring the choice of medication to the needs of the individual patient. Drs. Wigginton and Higginbotham review the benefits of beta-blockers and present some of the disadvantages of the non-beta-blocker class of medications.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11801272     DOI： 10.1016/s0039-6257(01)00286-7

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN： 0039-6257            Impact factor:   6.048


  10 in total

1.  The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.

Authors:  Jillian G Baker
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

2.  The effect of previous surgery and topical eye drops for primary open-angle glaucoma on cytokine expression in aqueous humor.

Authors:  Lisa A Engel; Philipp S Muether; Sascha Fauser; Arno Hueber
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-03-18       Impact factor: 3.117

3.  Medical and surgical outcomes in childhood glaucoma: a population-based study.

Authors:  Elisabeth P Aponte; Nancy Diehl; Brian G Mohney
Journal:  J AAPOS       Date:  2011-06-11       Impact factor: 1.220

Review 4.  Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems.

Authors:  Nicholas Bodor; Peter Buchwald
Journal:  AAPS J       Date:  2005-12-07       Impact factor: 4.009

5.  Clinical options for the reduction of elevated intraocular pressure.

Authors:  Laura Crawley; Sohaib M Zamir; Maria F Cordeiro; Li Guo
Journal:  Ophthalmol Eye Dis       Date:  2012-04-30

Review 6.  Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling.

Authors:  Jillian G Baker; Stephen J Hill; Roger J Summers
Journal:  Trends Pharmacol Sci       Date:  2011-03-21       Impact factor: 14.819

7.  Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses.

Authors:  Jillian G Baker; Philip Kemp; Julie March; Laurice Fretwell; Stephen J Hill; Sheila M Gardiner
Journal:  FASEB J       Date:  2011-08-24       Impact factor: 5.191

8.  Efficacy and Tolerability of Travoprost 0.004%/Timolol 0.5% Fixed-Dose Combination for the Treatment of Primary Open-Angle Glaucoma or Ocular Hypertension Inadequately Controlled with Beta-Blocker Monotherapy.

Authors:  Simon Fabian Lerner; Ki Ho Park; Douglas A Hubatsch; Valeriy Erichev; Jose A Paczka; Timothy V Roberts
Journal:  J Ophthalmol       Date:  2017-01-23       Impact factor: 1.909

9.  A Randomized, Double-Masked, Active-Controlled, Crossover Phase III Equivalence Study of Generic Dorzolamide 2% versus Innovator Trusopt® Eye Drop Solution in Subjects with Open-Angle Glaucoma or Ocular Hypertension.

Authors:  Katharina Bell; Christina Korb; Christina Butsch; Bert Constantin Giers; Anna Beck; Alicja Strzalkowska; Christian Ruckes; Ulrike Klingberg; Norbert Pfeiffer; Katrin Lorenz
Journal:  J Ophthalmol       Date:  2022-07-20       Impact factor: 1.974

Review 10.  Promising Approach in the Treatment of Glaucoma Using Nanotechnology and Nanomedicine-Based Systems.

Authors:  Fidiniaina Rina Juliana; Samuel Kesse; Kofi Oti Boakye-Yiadom; Hanitrarimalala Veroniaina; Huihui Wang; Meihao Sun
Journal:  Molecules       Date:  2019-10-22       Impact factor: 4.411
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.